Alimera Announces Scientific Data Highlighting YUTIQ® to be Presented at Upcoming Association for Research in Vision and Ophthalmology and Retina World Congress Conferences
May 07 2024 - 8:00AM
Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global
pharmaceutical company whose mission is to be invaluable to
patients, physicians and partners concerned with retinal health and
maintaining better vision longer, announced today it will have
three scientific abstracts at two upcoming ophthalmic congresses
including the Association for Research in Vision and Ophthalmology
(ARVO) conference, scheduled in Seattle, WA. from May 5 - 9 and
Retina World Congress (RWC) scheduled in Fort Lauderdale, FL. from
May 9 - 13.
ARVO Key Abstracts:
- Tue, May 07 8:30am - 10:15am PT; Tedi Begaj, MD; Lisa
Faia, MDCALM: 24-Month Safety Outcomes From a Real-World Registry
Study of Patients with Chronic Non-infectious Uveitis Affecting the
Posterior Segment Treated with the 0.18 mg Fluocinolone Acetonide
Intravitreal Implant (Poster A0170)
- Thu, May 09 2:30pm -
2:45pm PT; Phoebe Lin, MDCALM: 24-Month Retinal Thickness Outcomes
From a Real-World Registry Study of Patients with Chronic
Non-infectious Uveitis Affecting the Posterior Segment Treated with
the 0.18 mg Fluocinolone Acetonide Intravitreal Implant (Abstract
#6454)
RWC Key Abstract:
- Poster-on-demand, Michael Singer, MD36-month Outcomes Following
Treatment of Chronic Non-infectious Uveitis Affecting the Posterior
Segment with the 0.18 mg Fluocinolone Acetonide Intravitreal
Implant: a CALM Registry Analysis
About YUTIQYUTIQ is a sustained release
fluocinolone acetonide intravitreal implant injected into the back
of the eye using CONTINUOUS MICRODOSING™ technology, which is
designed to release sub-microgram levels of fluocinolone acetonide,
a corticosteroid, for up to 36 months, to reduce the recurrence of
disease and enable patients to maintain vision longer with fewer
injections. YUTIQ helps provide CONTINUOUS CALM™ by reducing
recurrence of inflammation in the treatment of chronic
non-infectious uveitis affecting the posterior segment of the eye.
For more information, please visit www.YUTIQ.com
About Alimera Sciences, Inc.Alimera Sciences is
a global pharmaceutical company whose mission is to be invaluable
to patients, physicians and partners concerned with retinal health
and maintaining better vision longer. For more information, please
visit www.alimerasciences.com.
For press inquiries:Cassy Dumpfor Alimera Sciences
619-971-1887cassy@heyshine.com |
For investor inquiries:Scott Gordonfor Alimera
Sciencesscottg@coreir.com |
Alimera Sciences (NASDAQ:ALIM)
Historical Stock Chart
From Jun 2024 to Jul 2024
Alimera Sciences (NASDAQ:ALIM)
Historical Stock Chart
From Jul 2023 to Jul 2024